EGRX
Income statement / Annual
Last year (2022), Eagle Pharmaceuticals, Inc.'s total revenue was $316.61 M,
an increase of 84.56% from the previous year.
In 2022, Eagle Pharmaceuticals, Inc.'s net income was $35.64 M.
See Eagle Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
09/30/2014 |
09/30/2013 |
Operating Revenue |
$316.61 M |
$171.55 M |
$187.80 M |
$195.89 M |
$213.31 M |
$236.71 M |
$189.48 M |
$66.23 M |
$19.10 M |
$13.68 M |
Cost of Revenue |
$94.94 M
|
$42.18 M
|
$45.47 M
|
$60.90 M
|
$61.92 M
|
$57.19 M
|
$55.31 M
|
$15.65 M
|
$11.71 M
|
$7.38 M
|
Gross Profit |
$221.67 M
|
$129.37 M
|
$142.34 M
|
$135.00 M
|
$151.40 M
|
$179.52 M
|
$134.18 M
|
$50.58 M
|
$7.39 M
|
$6.30 M
|
Gross Profit Ratio |
0.7
|
0.75
|
0.76
|
0.69
|
0.71
|
0.76
|
0.71
|
0.76
|
0.39
|
0.46
|
Research and Development Expenses |
$34.09 M
|
$51.28 M
|
$30.79 M
|
$36.81 M
|
$44.42 M
|
$32.61 M
|
$30.26 M
|
$27.86 M
|
$16.82 M
|
$9.80 M
|
General & Administrative Expenses |
$98.13 M
|
$66.82 M
|
$75.90 M
|
$73.97 M
|
$57.21 M
|
$73.07 M
|
$37.53 M
|
$15.41 M
|
$5.02 M
|
$0.00
|
Selling & Marketing Expenses |
$8.50 M
|
$8.50 M
|
$2.70 M
|
$2.40 M
|
$3.30 M
|
-$1.65 M
|
$14.78 M
|
$4.75 M
|
$4.30 M
|
$0.00
|
Selling, General & Administrative Expenses |
$106.63 M
|
$75.32 M
|
$78.60 M
|
$76.37 M
|
$60.51 M
|
$71.42 M
|
$52.31 M
|
$20.17 M
|
$9.33 M
|
$4.96 M
|
Other Expenses |
$0.00
|
-$6.24 M
|
-$8.26 M
|
$700,000.00
|
$52.23 M
|
$35.22 M
|
$32.57 M
|
$0.00
|
$35,000.00
|
$3,202.00
|
Operating Expenses |
$140.71 M
|
$126.60 M
|
$109.38 M
|
$113.18 M
|
$104.93 M
|
$104.02 M
|
$82.58 M
|
$48.02 M
|
$26.14 M
|
$14.75 M
|
Cost And Expenses |
$235.65 M
|
$168.78 M
|
$154.85 M
|
$174.08 M
|
$166.84 M
|
$161.21 M
|
$137.88 M
|
$63.67 M
|
$37.86 M
|
$22.13 M
|
Interest Income |
$271,000.00
|
$560,000.00
|
$562,000.00
|
$2.17 M
|
$158,000.00
|
$91,000.00
|
$84,000.00
|
$25,000.00
|
$31,000.00
|
$3,212.00
|
Interest Expense |
$4.05 M
|
$1.64 M
|
$2.58 M
|
$2.69 M
|
$2.74 M
|
$1.14 M
|
$8,000.00
|
$11,000.00
|
$8,000.00
|
$1.40 M
|
Depreciation & Amortization |
$12.02 M
|
$4.81 M
|
$4.77 M
|
$4.65 M
|
$3.67 M
|
$3.75 M
|
$1.59 M
|
$112,000.00
|
$104,000.00
|
$134,994.00
|
EBITDA |
$77.50 M |
$2.77 M |
$30.02 M |
$28.18 M |
$40.44 M |
$77.83 M |
$55.02 M |
$2.70 M |
-$18.76 M |
-$8.41 M |
EBITDA Ratio |
0.24
|
0
|
0.16
|
0.15
|
0.24
|
0.34
|
0.27
|
0.04
|
-0.98
|
-0.61
|
Operating Income Ratio |
0.26
|
-0.02
|
0.13
|
0.11
|
0.17
|
0.31
|
0.28
|
0.04
|
-0.98
|
-0.62
|
Total Other Income/Expenses Net |
-$19.53 M
|
-$7.32 M
|
-$10.28 M
|
$183,000.00
|
-$2.58 M
|
-$1.05 M
|
$76,000.00
|
$14,000.00
|
-$515,000.00
|
$1.51 M
|
Income Before Tax |
$61.43 M
|
-$4.55 M
|
$22.68 M
|
$22.00 M
|
$34.04 M
|
$72.95 M
|
$53.43 M
|
$2.57 M
|
-$19.27 M
|
-$6.95 M
|
Income Before Tax Ratio |
0.19
|
-0.03
|
0.12
|
0.11
|
0.16
|
0.31
|
0.28
|
0.04
|
-1.01
|
-0.51
|
Income Tax Expense |
$25.79 M
|
$4.08 M
|
$10.69 M
|
$7.69 M
|
$2.14 M
|
$21.00 M
|
-$28.03 M
|
$3,000.00
|
-$1.30 M
|
-$898,703.00
|
Net Income |
$35.64 M
|
-$8.63 M
|
$11.99 M
|
$14.31 M
|
$31.90 M
|
$51.94 M
|
$81.45 M
|
$2.57 M
|
-$17.98 M
|
-$6.05 M
|
Net Income Ratio |
0.11
|
-0.05
|
0.06
|
0.07
|
0.15
|
0.22
|
0.43
|
0.04
|
-0.94
|
-0.44
|
EPS |
2.76 |
-0.66 |
0.89 |
1.04 |
2.16 |
3.44 |
5.24 |
0.17 |
-1.81 |
-0.57 |
EPS Diluted |
2.73 |
-0.66 |
0.87 |
1.01 |
2.09 |
3.27 |
4.96 |
0.16 |
-1.81 |
-0.57 |
Weighted Average Shares Out |
$12.93 M
|
$13.05 M
|
$13.48 M
|
$13.75 M
|
$14.77 M
|
$15.10 M
|
$15.53 M
|
$15.25 M
|
$9.96 M
|
$10.57 M
|
Weighted Average Shares Out Diluted |
$13.07 M
|
$13.05 M
|
$13.77 M
|
$14.14 M
|
$15.28 M
|
$15.91 M
|
$16.43 M
|
$16.25 M
|
$9.96 M
|
$10.57 M
|
Link |
|
|
|
|
|
|
|
|
|
|